Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.

2.50
Hdl Handle:
http://hdl.handle.net/2336/4513
Title:
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.
Authors:
Hawkey, C J; Atherton, J C; Treichel, H C; Thjodleifsson, B; Ravic, M
Citation:
Aliment. Pharmacol. Ther. 2003, 17(8):1065-74
Issue Date:
1-Apr-2003
Abstract:
AIM: A double-blind, randomized study was designed to determine whether rabeprazole- and omeprazole-based triple therapy regimens are therapeutically equivalent in the eradication of Helicobacter pylori. METHODS: Three hundred and forty-five patients with current or previously active peptic ulcer and a positive H. pylori urease test were randomly assigned to receive RCA, OCA, RCM or OCM twice daily for 7 days (R, rabeprazole 20 mg; O, omeprazole 20 mg; C, clarithromycin 500 mg; A, amoxicillin 1000 mg; M, metronidazole 400 mg). H. pylori eradication was documented by negative 13C-urea breath tests at 4 and 12 weeks, and was evaluated using a 2 x 2 factorial design with proton pump inhibitor and antibiotic as factors. RESULTS: Overall eradication rates (per protocol/intention-to-treat) were 87%/77% and 85%/75% with rabeprazole and omeprazole, respectively (not significant). However, a statistical interaction between proton pump inhibitor and antibiotic was identified. RCA produced a somewhat higher eradication rate than OCA (94% vs. 84%; difference, 9.8%; 95% confidence interval, - 0.7% to + 20.4%), whereas RCM produced a lower eradication rate than OCM (79% vs. 86%; difference, 8.1%; 95% confidence interval, - 21.4% to + 5.1%). Ulcer healing rates were > 90% with H. pylori eradication. Each regimen was well tolerated. CONCLUSIONS: Rabeprazole- and omeprazole-based triple therapy regimens are therapeutically equivalent in the eradication of H. pylori and well tolerated. The statistical interaction observed between the proton pump inhibitor and supplementary antibiotic may be due to chance.
Additional Links:
http://www.blackwell-synergy.com/doi/full/10.1046/j.1365-2036.2003.01492.x

Full metadata record

DC FieldValue Language
dc.contributor.authorHawkey, C J-
dc.contributor.authorAtherton, J C-
dc.contributor.authorTreichel, H C-
dc.contributor.authorThjodleifsson, B-
dc.contributor.authorRavic, M-
dc.date.accessioned2006-09-20T16:34:36Z-
dc.date.available2006-09-20T16:34:36Z-
dc.date.issued2003-04-01-
dc.identifier.citationAliment. Pharmacol. Ther. 2003, 17(8):1065-74en
dc.identifier.issn0269-2813-
dc.identifier.pmid12694089-
dc.identifier.doidoi:10.1046/j.1365-2036.2003.01492.xen
dc.identifier.otherGAS12-
dc.identifier.urihttp://hdl.handle.net/2336/4513-
dc.description.abstractAIM: A double-blind, randomized study was designed to determine whether rabeprazole- and omeprazole-based triple therapy regimens are therapeutically equivalent in the eradication of Helicobacter pylori. METHODS: Three hundred and forty-five patients with current or previously active peptic ulcer and a positive H. pylori urease test were randomly assigned to receive RCA, OCA, RCM or OCM twice daily for 7 days (R, rabeprazole 20 mg; O, omeprazole 20 mg; C, clarithromycin 500 mg; A, amoxicillin 1000 mg; M, metronidazole 400 mg). H. pylori eradication was documented by negative 13C-urea breath tests at 4 and 12 weeks, and was evaluated using a 2 x 2 factorial design with proton pump inhibitor and antibiotic as factors. RESULTS: Overall eradication rates (per protocol/intention-to-treat) were 87%/77% and 85%/75% with rabeprazole and omeprazole, respectively (not significant). However, a statistical interaction between proton pump inhibitor and antibiotic was identified. RCA produced a somewhat higher eradication rate than OCA (94% vs. 84%; difference, 9.8%; 95% confidence interval, - 0.7% to + 20.4%), whereas RCM produced a lower eradication rate than OCM (79% vs. 86%; difference, 8.1%; 95% confidence interval, - 21.4% to + 5.1%). Ulcer healing rates were > 90% with H. pylori eradication. Each regimen was well tolerated. CONCLUSIONS: Rabeprazole- and omeprazole-based triple therapy regimens are therapeutically equivalent in the eradication of H. pylori and well tolerated. The statistical interaction observed between the proton pump inhibitor and supplementary antibiotic may be due to chance.en
dc.language.isoenen
dc.publisherBlackwell Scientific Publicationsen
dc.relation.urlhttp://www.blackwell-synergy.com/doi/full/10.1046/j.1365-2036.2003.01492.xen
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAmoxicillinen
dc.subject.meshAnti-Ulcer Agentsen
dc.subject.meshBenzimidazolesen
dc.subject.meshClarithromycinen
dc.subject.meshDouble-Blind Methoden
dc.subject.meshDrug Therapy, Combinationen
dc.subject.meshFemaleen
dc.subject.meshHelicobacter Infectionsen
dc.subject.meshHelicobacter pylorien
dc.subject.meshOmeprazoleen
dc.subject.meshPeptic Ulceren
dc.subject.meshProton Pumpsen
dc.subject.meshResearch Support, Non-U.S. Gov'ten
dc.subject.meshSafetyen
dc.titleSafety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease.en
dc.typeArticleen
dc.format.digYES-

Related articles on PubMed

All Items in Hirsla are protected by copyright, with all rights reserved, unless otherwise indicated.